Medication info
Yuhan Metformin Extended-Release Tablets 750mg (Metformin Hydrochloride)

Yuhan Metformin Extended-Release Tablets 750mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›750mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Pink, rectangular film-coated tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201405356 · Approved 2014.11.18 · Insurance code 642104630

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on the drug's efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a once-daily dose of up to 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this preparation is the same as the daily dose of immediate-release metformin tablets. Switching to this preparation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At the start of treatment and when adjusting the dose, fasting blood glucose should be measured to assess the response to treatment with this medicine and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured at approximately 3-month intervals. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, this medicine must be discontinued immediately.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used to assist in blood sugar management for adult patients with type 2 diabetes when dietary and exercise regimens alone are insufficient, particularly for individuals who are overweight. It may be taken alone or in combination with other oral hypoglycemic agents or insulin to enhance therapeutic effects. This helps to effectively control blood sugar levels and aids in diabetes treatment.

How to take

Adult dose

The dose should be determined individually based on the drug's efficacy and tolerability, and should not exceed the recommended maximum daily dose. - The usual starting dose is metformin hydrochloride extended-release tablets 500mg once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a once-daily dose of up to 2000mg, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this preparation is the same as the daily dose of immediate-release metformin tablets. Switching to this preparation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - At the start of treatment and when adjusting the dose, fasting blood glucose should be measured to assess the response to treatment with this medicine and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured at approximately 3-month intervals. - The goal of treatment with this medicine, whether administered as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate decreases to less than 45ml/min or 45ml/min/1.73m2, respectively, this medicine must be discontinued immediately.

Precautions

This medication can rarely cause a serious condition known as lactic acidosis, which can endanger life. When used in combination with other diabetes medications, hypoglycemic symptoms may occur, so caution is needed. It should not be administered to patients with moderate to severe renal impairment, those who are dehydrated, or those experiencing acute conditions such as severe infections, acute myocardial infarction, sepsis, etc. Patients with unstable heart failure or those undergoing tests involving iodinated contrast agents should not use this medication. It is also contraindicated in patients who have allergies to any components of this medication, in patients with type 1 diabetes, and those with metabolic acidosis. Patients experiencing severe infections or serious trauma that may affect their generalized condition should temporarily cease medication, and discontinuation is advised for a certain period before and after surgery. Use should be avoided in patients with extremely poor nutritional status, liver dysfunction, or excessive alcohol consumption. Pregnant women at risk of placental dysfunction or preeclampsia should avoid using this medication. Careful consideration should be given when administering this medication to patients with irregular meals, excessive exercise, or who are taking interacting medications. While taking this medication, side effects such as vitamin B12 deficiency, gastrointestinal disturbances (nausea, vomiting, diarrhea, etc.), and skin rashes may occur, therefore caution is necessary. Gastrointestinal disturbances, in particular, commonly appear in the early stages of treatment and may be alleviated by gradually increasing the dose or taking it with food. Monitoring renal function is very important and if renal function worsens, medication should be discontinued. Alcohol can increase the risk of lactic acidosis, so excessive drinking should be avoided while on this medication. Because it can interact with other drugs, patients should inform their physician or pharmacist about any medications they are currently taking. Blood sugar control is crucial during pregnancy as this medication crosses the placenta, so pregnant women should consult with their doctor before use. If breastfeeding, a careful decision needs to be made regarding whether to continue breastfeeding as this medication is excreted in breast milk. Safety in pediatric patients has not been established, and it is not recommended for those under 17 years of age. Elderly patients are at higher risk of renal function decline, therefore dosage adjustment and regular renal function monitoring are necessary. In cases of overdose, blood dialysis may be necessary, and immediate medical attention should be sought. This medication should not be crushed or chewed; it should be swallowed whole, and the tablet shell may appear in stool, which is normal. Regular blood glucose monitoring and renal function assessment should be conducted during treatment to verify therapeutic effectiveness and safety.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste distortion
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • appetite loss
  • erythema
Show 3 more
  • itching
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, avoid extremely hot or cold locations, and it is recommended to store it at room temperature between 1 degree and 30 degrees.

Appearance and packaging

Appearance

Pink, rectangular film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.